Therapeutic Drug Monitoring
Celltrion Testing Access Program
Optimize treatment for patients transitioning to subcutaneous infliximab (SC-IFX) therapy from intravenous (IV) IFX.
The Celltrion Testing Access Program provides Anser® IFX therapeutic drug monitoring at no cost for eligible patients* who are candidates to transition to SC-IFX.
Why use therapeutic drug monitoring during the transition from IV- to SC-IFX?
- Gain important data to help optimize your patient’s treatment journey
- Before switching, assess IV‑IFX trough concentrations and antibodies to evaluate response and stability
- Post-transition to SC-IFX, confirm adequate exposure and establish an IFX-SC baseline
- Consider therapeutic adjustments in conjunction with clinical presentation for durable drug response
Who is eligible?
- Candidates for SC IFX currently maintained on IV IFX
- 18 years of age or older
- Commercially insured or uninsured
Simple steps to obtain high-quality testing that supports your patient’s care
Anser is part of the Prometheus continuum of care for IBD patients
*Phlebotomy-related costs may be incurred at non-participating locations.
Anser IFX was developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) laboratory guidelines, and is performed exclusively in our high complexity CLIA certified and College of American Pathologists accredited clinical laboratory. As a laboratory-developed test, it has not been cleared or approved by the US FDA. The test may be covered by one or more US pending or issued patents – see prometheuslabs.com/patents. Prometheus and Anser are registered trademarks of Prometheus Laboratories Inc.; all rights reserved. All other trademarks are property of their respective owners. This material is provided for general information purposes only as an educational service for healthcare providers. It is not intended to substitute for medical advice and/or consultation with a physician.